What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Fenofibrate for diabetic retinopathy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention leads to higher SAEa (high certainty).

• Fenofibrate for diabetic retinopathy 2023 · Cochrane Headline outcomes only
  RR 1.55 [1.05, 2.27]
  2 studies · 15226 participants
  High

Immune checkpoint inhibitors vs any first‐line chemotherapy

Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  HR 0.97 [0.87, 1.07]
  3 studies · 2068 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Immune checkpoint inhibitors vs any second‐line chemotherapy

It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  HR 0.99 [0.84, 1.16]
  2 studies · 1473 participants
  Very low

Immune checkpoint inhibitors vs any second‐line chemotherapy

Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  RR 0.35 [0.17, 0.72]
  2 studies · 1473 participants
  Low

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any first‐line chemotherapy

Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  RR 0.47 [0.29, 0.75]
  3 studies · 2046 participants
  Moderate

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Immune checkpoint inhibitors vs any first‐line chemotherapy

Immune checkpoint inhibitors probably leads to higher time to disease progression Range of compared with any first‐line chemotherapy (moderate certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  HR 1.33 [1.17, 1.5]
  2 studies · 1349 participants
  Moderate

Immune checkpoint inhibitors vs any first‐line chemotherapy

Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  RR 0.47 [0.2, 1.1]
  3 studies · 2046 participants
  Low

Immune checkpoint inhibitors vs any second‐line chemotherapy

Immune checkpoint inhibitors may leads to lower time to death from any cause Range of compared with any second‐line chemotherapy (low certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  HR 0.72 [0.63, 0.81]
  2 studies · 1473 participants
  Low

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low

Immune checkpoint inhibitors vs any second‐line chemotherapy

Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.81, 0.97]
  2 studies · 1423 participants
  Low

Intervention not reported

The intervention showed no clear difference in poor outcome (high certainty).

• Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.94, 1.13]
  5 studies · 2359 participants
  High

Intervention not reported

The intervention showed no clear difference in all cause mortality (high certainty).

• Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage 2022 · Cochrane Headline outcomes only
  RR 1.02 [0.9, 1.16]
  11 studies · 2717 participants
  High

Intervention not reported

The intervention probably leads to lower rebleeding (moderate certainty).

• Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.47, 0.91]
  11 studies · 2717 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in delayed cerebral ischemia (moderate certainty).

• Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage 2022 · Cochrane Headline outcomes only
  RR 1.27 [1, 1.62]
  7 studies · 2484 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in hydrocephalus (high certainty).

• Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage 2022 · Cochrane Headline outcomes only
  RR 1.09 [0.99, 1.2]
  6 studies · 1992 participants
  High

Paracetamol vs ibuprofen

Paracetamol showed no clear difference in failure of PDA closure after first course of treatment (assessed by… compared with ibuprofen (moderate certainty).

• Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
  RR 1.02 [0.88, 1.18]
  18 studies · 1535 participants
  Moderate